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ABSTRACT
Photodynamic therapy (PDT) can treat superficial, early-
stage disease with minimal damage to underlying tissues and
without cumulative dose-limiting toxicity. Treatment efficacy
is affected by disease physiologic properties, but these prop-
erties are not routinely measured. We assessed diffuse reflec-
tance spectroscopy (DRS) for the noninvasive, contact
measurement of tissue hemoglobin oxygen saturation (StO2)
and total hemoglobin concentration ([tHb]) in the premalig-
nant or superficial microinvasive oral lesions of patients
treated with 5-aminolevulinic acid (ALA)-PDT. Patients were
enrolled on a Phase 1 study of ALA-PDT that evaluated flu-
ences of 50, 100, 150 or 200 J cm2 delivered at
100 mW cm2. To test the feasibility of incorporating DRS
measurements within the illumination period, studies were
performed in patients who received fractionated (two-part)
illumination that included a dark interval of 90–180 s. Using
DRS, tissue oxygenation at different depths within the lesion
could also be assessed. DRS could be performed concur-
rently with contact measurements of photosensitizer levels
by fluorescence spectroscopy, but a separate noncontact fluo-
rescence spectroscopy system provided continuous assess-
ment of photobleaching during illumination to greater tissue
depths. Results establish that the integration of DRS into
PDT of early-stage oral disease is feasible, and motivates
further studies to evaluate its predictive and dosimetric
value.
INTRODUCTION
Photodynamic therapy (PDT) is well-suited to the treatment of
early-stage head and neck malignancies as it produces a superfi-
cial effect that preserves the structure and function of underlying
and adjacent tissues (1,2). Head and neck squamous cell carci-
noma (HNSCC) is the sixth most common cancer reported glob-
ally (3) with 5-year survival rates ranging from 36.3 to 82.7%
depending on tumor location and stage at diagnosis (4). Multiple
clinical trials and series using PDT with either temoporfin or por-
fimer sodium in patients with T0–T2 N0 HNSCC have been
reported, demonstrating complete response rates of 85–90% (5).
Given the natural history of early HNSCC with patients typically
experiencing multiple metachronous lesions, one key advantage
for PDT is that, unlike radiotherapy, multiple treatment courses
can be performed without accumulating additional risk for toxic-
ity (6). On a temporary basis, however, prolonged cutaneous
photosensitivity from temoporfin or porfimer sodium can be
logistically challenging for patients. In this trial, we have
investigated the use of 5-aminolevulinic acid (ALA), a photosen-
sitizer-inducing prodrug that is tailored to superficial treatment
applications and exhibits short duration (2 days) for cutaneous
photosensitivity.
The oxygenation status of a tumor is critical to PDT response.
Paradoxically, PDT can itself deplete oxygen levels through the
oxygen-dependent photochemical reaction, as well as through the
damage of tumor vasculature (2,7). Indeed, PDT-induced vascu-
lar destruction, indicated by blood flow stasis and hemorrhage of
the microvasculature, has been observed in oral squamous cell
carcinomas (SCC) using side-stream dark field imaging (8).
While vascular shutdown can be beneficial to tumor destruction
by effectively inducing tumor ischemia, if ischemia occurs dur-
ing the course of light delivery, it may impede the therapeutic
effect by exacerbating photochemically induced hypoxia or by
independently producing a hypoxic state. One approach to cir-
cumvent this effect is to fractionate the treatment light. This is
based on the hypothesis that interruption of the light delivery
may partially reverse the treatment-induced hypoxia by allowing
for reperfusion of the tissue (2). The importance of maintaining
sufficient oxygen levels during PDT is paramount to treatment
efficacy. Our group has reported that PDT-induced changes in
tumor hemoglobin oxygen saturation (StO2) correlate with treat-
ment response in preclinical investigations (9). Pogue et al. (10)
reported that ALA-PDT can produce increases in pO2 during
light treatment, though these increases were highly variable from
mouse-to-mouse. This variability emphasizes the need to monitor
oxygenation status during PDT on a case-by-case basis, as it
highlights the inherent differences in tumor microenvironment
across patients.
Optical methods to monitor photodynamic therapy have been
developed in a variety of settings previously. The most useful of
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these generally fall into two categories: Absorption-based detec-
tion used to quantify hemodynamic parameters, and fluorescence
spectroscopy or imaging used to detect photosensitizer via its flu-
orescence emission (11). Diffuse reflectance measurements have
been widely used to characterize hemodynamics during PDT.
Optical absorption measurements using compact, fiber-based
probes can detect hemoglobin oxygen concentration and satura-
tion (12) and relative changes in blood flow (13). However,
diffuse reflectance technologies have difficulty detecting the pho-
tosensitizer, ALA-induced protoporphyrin IX (PpIX), due to its
low absorption relative to hemoglobin. In contrast, fluorescence
can be used to quantify the uptake of photosensitizer in tissue.
For instance, Zhou et al. (14) demonstrated in an animal model
that adjusting light dose to account for variations in pretreatment
sensitizer fluorescence led to more consistent responses to PDT.
The sensitizer concentration can be therefore used in an explicit
dosimetric model to predict response to PDT. It is also possible
to use the photobleaching of the sensitizer as an implicit dosi-
metric surrogate for PDT response (15). ALA-induced PpIX is
highly fluorescent, and readily photobleaches due to reactions
with the singlet oxygen it generates, making it an ideal candidate
for the implicit dosimetry. This has been demonstrated in animal
models (16,17), and utilized to reduce pain in a clinical trial of
PDT for superficial skin lesions (18). Recent work in our group
has focused on developing combined instrumentation for reflec-
tance and fluorescence detection compatible with clinical trials of
PDT. We have implemented absorption and fluorescence detec-
tion in interstitial treatments of the human prostate (19,20) and
intraoperative trials in the peritoneal (21) and pleural (22)
settings.
In this study, we present results pertaining to a clinical trial of
ALA-PDT for premalignant and early microinvasive lesions of
the oral cavity for which diffuse reflectance spectroscopy (DRS)
and fluorescence spectroscopy were employed to, respectively,
monitor lesion oxygenation and photosensitizer levels during
PDT. Results establish that it is feasible to incorporate contact-
based DRS measurements into the course of the illumination of
oral lesions to determine lesion oxygenation before, during a 90–
180 s dark interval for fractionation, and immediately after treat-
ment. Using a contact probe, photosensitizer photobleaching can
be measured concurrently with the physiologic data at discrete
timepoints. In contrast, a noncontact fluorescence spectroscopy
system provides the means for continuous monitoring of relative
photosensitizer levels during illumination of the lesions. Data
demonstrate that ALA-PDT creates measureable, patient-specific
changes in the physiologic properties of oral lesions that can be
analyzed in a depth-dependent manner. Early outcome data sup-
port the design of a prospective study to determine whether
lesion StO2 is predictive of clinical outcomes in PDT of oral
disease.
MATERIALS AND METHODS
Clinical trial. These studies were conducted as part of a Phase 1 prospec-
tive clinical trial of ALA-PDT for the treatment of premalignant or super-
ficial microinvasive disease of the head and neck. The protocol was
conducted under an investigator-sponsored IND with the U.S. Food and
Drug Administration. This study was performed in accordance with the
Declaration of Helsinki and had approval from the Institutional Review
Board of the University of Pennsylvania and the University of Pennsylva-
nia Clinical Trials Scientific Review and Monitoring Committee. Patients
with biopsy-confirmed disease received an oral dose (60 mg kg1) of
ALA (kindly supplied by DUSA Pharmaceuticals, Inc, Wilmington, MA)
followed in 4–6 h by the administration of red light to the visualized
lesion. Patients were maintained under general anesthesia for the duration
of spectroscopy measurements and PDT. Light was delivered using either
a microlens (MedLight SA, Ecublens, Switzerland) or with a balloon
diffusing fiber (MedLight SA) that has previously been described (23).
A Cerelas Series GaA1As 4W diode laser (Biolitec, Inc., East Long-
meadow, MA) emitting at a peak wavelength of 632 nm (90% of the
power within 629–635 nm) was used as the light source. Light was
delivered to the surface of the lesion at a fluence rate of 100 mW cm2
as measured by a calibrated isotropic detector that was placed on the tar-
get surface at the initiation of illumination. Differences in geometry and
optical properties among patients lead to variations in the amount of scat-
tered light that contributes to the signal measured by this detector. The
incident irradiance was modified to ensure that the fluence rate at the
lesion surface (including light scattered from the tissue) was maintained
at the prescribed fluence rate. As needed, intraoperative light shielding of
the surrounding normal tissue was performed using blue surgical towels
or by painting with a solution of methylene blue. Light precautions were
observed for 48 h after ALA ingestion and included the filtering of oper-
ating room lights and the protection of the patients’ exposed skin with
drapes or clothing.
This was a dose escalation trial in which fluences of 50, 100, 150 and
200 J cm2 were tested. At each fluence, patients received either continu-
ous or fractionated illumination, thus the study consisted of a total of
eight cohorts (each fluence, with or without fractionation). Randomization
between continuous and fractionated treatment was initiated after comple-
tion of the first two cohorts, one at 50 J cm2 with continuous illumina-
tion and one at 50 J cm2 with fractionated light. Consequently, doses
above 50 J cm2 were designated as cohorts 3 (100 J cm2), 4
(150 J cm2) and 5 (200 J cm2), with the addition of “a” versus “b”
for continuous and fractionated illumination, respectively. Three patients
were treated per cohort, expanded to six patients if treatment resulted in
a dose-limiting toxicity (DLT). DLTs were defined as the presence of a
grade 3 or higher toxicity at 30 days after PDT; toxicities were evaluated
and scored using the Cooperative Group Common Toxicity Criteria
(CTCAE v.3.0). No patients were treated above the maximum tolerated
dose, defined as the light dose level which resulted in no more than one
DLT in six treated patients and for which the next higher dose level pro-
duced two or more DLTs in three to six treated patients. Follow up was
performed on day 1, ~week 1, ~week 2–3, ~day 30, ~day 90, every
3 months for 24 months and then annually (day 0 defined as the day of
PDT). At the 90 day follow-up a clinical evaluation of response was per-
formed. Patients were scored for a complete response, which was defined
as complete ablation or absence of the index lesion in the area treated
with light. In the absence of a complete response, the presence of local
recurrence was noted.
This report considers only those patients who received fractionated
illumination. Fractionation was defined by delivery of 20% of the fluence
followed by a 90–180 s break in illumination before resuming treatment
to the full fluence (24). The length of the dark interval allowed for the
integration of spectroscopy measurements when treatment was at an
accessible site. In these patients, spectroscopy measurements of the
lesion, as defined below, were made prior to light delivery, during the
dark interval for fractionation, and after the completion of light delivery.
Of note, in patient 7, the break for fractionation occurred after 20% of
200 J cm2 had been delivered although the patient received
150 J cm2. This was a result of the early termination of light delivery
at 150 J cm2 of a planned dose of 200 J cm2. Also, only one patient
treated at 100 J cm2 had a lesion that was accessible for spectroscopy
measurements. Normal tissue of tongue, buccal mucosa or hard palate
was measured in each patient before and after light delivery.
Instrumentation. The spectroscopic data presented here were collected
by each of two independent systems. The first, the contact fluorescence
and reflectance spectroscopy (CFRS) system, uses a custom-built fiber-
optic based optical probe, which is placed in physical contact with the
tissue being treated prior to, immediately after and during a brief inter-
ruption in illumination. This probe consists of two source optical fibers
and a series of detection fibers spaced between 0.14 and 0.88 cm away
from the first source fiber. The probe allows collection of diffuse reflec-
tance using a white light source (Avalight; Avantes, Broomfield, CO)
coupled to the first source fiber, and fluorescence spectra using a 403 nm
excitation laser (Power Technologies, Inc., Little Rock, AK) coupled to
the second source fiber. Both measurements use the same set of detection
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fibers, which are imaged by an integrated imaging spectrometer/multi-
channel CCD system (Inspectrum; Roper Scientific, Trenton, NJ). Data
acquisition is sequential such that repeated diffuse reflectance, back-
ground and fluorescence spectra are acquired at each of multiple sample
locations. Data acquisition is triggered by an electronic push-button
interface that is controlled by the clinician.
The second spectroscopic measurement system, the noncontact treat-
ment fluorescence (NCTF) system, measures fluorescence emission
excited by the treatment light itself. This emission is collected by a pas-
sive, flat-cut optical fiber detector aligned to collect light from the treated
area. When a microlens is used for delivery of treatment light, the
detection fiber is held parallel to it. When a balloon diffuser is used, the
detector fiber is fixed such that its axis is aligned with the center of the
treatment field. The light collected by this fiber passes through a pair of
long-pass filters (OG 570; Schott North America, Inc., Duryea, PA and
RazorEdge LP02-633RU-25; Semrock, Rochester, NY) and is collected
by a single-channel, TE-cooled CCD spectrometer (BTC-112E; B&W
Tek, Newark, DE). The filters block treatment light and the primary
emission peak of PpIX, however, the long-wavelength secondary peak
around 707 nm is still distinguishable from the background of off-peak
laser emission and autofluorescence.
Data analysis. Data were analyzed in a combination of routines writ-
ten in Matlab (The Mathworks, Natick, MA). Briefly, the absorption
spectrum of tissue was assumed to be a linear combination of the
absorption spectra of oxy-and deoxyhemoglobin, weighted by their con-
centrations. The reduced scattering spectrum was assumed to follow the
form ls0 = A(k/k0)
b. This expression has been widely used to model
scattering from cells (25). The diffuse reflectance is modeled using the
P3-approximation-based expression developed by Hull and Foster (26), as
implemented by Finlay and Foster (12). The spectra from each source-
detector separation are fit independently. The fitting is performed in Mat-
lab using an iterative fitting algorithm (fminsearch). The free parameters
in the fit are A, b and the concentrations of oxy- and deoxyhemoglobin.
At each iteration, absorption and scattering spectra are constructed based
on these free parameters, and a theoretical diffuse reflectance spectrum is
calculated from the optical spectra. The process repeats until the calcu-
lated diffuse reflectance spectrum and the measured reflectance converge.
Because the lesions being evaluated are of limited size and the tissue cur-
vature may be extensive, only signal from the closest four fibers (with
source-detector distance of 0.34 cm or less) are selected to be included in
the analysis. From the determined quantities of oxyhemoglobin concen-
tration ([HbO2]) and deoxyhemoglobin concentration ([Hb]), tissue hemo-
globin oxygen saturation (StO2) was calculated as the ratio of [HbO2] to
total hemoglobin concentration ([tHb]), i.e. the sum of [HbO2] and [Hb]
and multiplied by 100 for reporting as a percentage.
Fluorescence spectra collected by the nearest fiber of the contact
probe to the source are corrected for the effects of absorption and scatter-
ing by dividing by the diffuse reflectance. The corrected spectra in the
range from 575 to 720 nm are then fit with a singular value decomposi-
tion (SVD)-based fitting algorithm (17). The basis spectra used to fit the
fluorescence data shown here are tissue autofluorescence, PpIX and two
fluorescent photoproducts of PpIX (17). The sensitivity of detection and
the geometry of illumination may vary from patient to patient. To correct
for this effect, the SVD amplitude of PpIX is divided by that of autofluo-
rescence. Results are therefore presented as fluorescence of PpIX per unit
autofluorescence.
Fluorescence excited by treatment light is fit with an SVD algorithm
analogous to that used for the contact probe measurements, but in this
case, only the portion of the spectrum from 660 nm to 730 nm is
included in the fit. Again, the results are reported as the PpIX signal
relative to autofluorescence.
Statistics. Data are summarized using means and medians. Wilcoxon
signed-rank tests were used to test for the presence of depth-dependent
differences in StO2 among detector positions. Hypothesis tests were two
sided, and statistical significance was declared for P-values <0.05.
RESULTS
Patient characteristics
A total of 14 patients were treated with fractionated (two-part)
light delivery. Fractionation incorporated a 90–180 s interruption
of light delivery after 20% of the total fluence was delivered.
Among these patients, 10 patients had lesions in the oral cavity
that were accessible to measurements before light delivery, dur-
ing the dark interval of fractionation and after PDT (Fig. 1). The
characteristics of these patients are summarized in Table 1. Med-
ian patient age was 61 (range 34–84) and nine of the patients
were female (patient 6 was male). Five patients had lesions on
the oral tongue, three had lesions where the tongue meets the
floor of the mouth or the alveolar ridge, and two of the patients
had lesions of the buccal mucosa. Histologically, the lesions ran-
ged from moderate dysplasia to microinvasive carcinoma for
lesions on the tongue or junction of the tongue, and moderate
dysplasia or carcinoma in situ for lesions of the buccal mucosa.
A complete clinical response was found at 3 months after PDT
in eight patients. Local recurrence occurred in patients 5 and 10.
Diffuse reflectance spectroscopy to measure physiologic
parameters
Physiologic parameters assessed in this study were obtained from
values for [HbO2] and [Hb] that were taken from fits to diffuse
reflectance spectra. A typical set of diffuse reflectance spectra
and their fitting is shown in Fig. 2a,b, respectively. In this figure,
the best-fit theoretical curve is plotted along with the measured
data. For comparison, the components of the absorption in this
spectral range are also shown. Because it is impossible to gener-
ate a theoretical reflectance curve in the absence of scattering,
these curves are generated assuming the best-fit scattering and
absorption composed of only one component (Hb or HbO2). The
agreement between the theoretical and measured data indicates
that the scattering model and two component absorbers are
sufficient to model the in vivo optical properties.
Tissue oxygenation, calculated as StO2, and blood volume,
calculated as [tHb], were determined from the fitted measure-
ments of [HbO2] and [Hb]. Figure 3a depicts lesion StO2 levels
at baseline, during the dark interval for fractionation, and after
the completion of light delivery in each patient. In Fig. 3b, val-
ues for [tHb] are shown. For both figures, data are plotted as a
function of the delivered light fluence, and, for simplicity, indi-
vidual panels depict patients treated at different light fluences.
Figure 1. Schematic of the CFRS system for diffuse reflectance/fluores-
cence spectroscopy. Sampling with the contact probe and the laser irradi-
ation are both shown. In reality, they are sequential. The probe face is
shown in the lower right. The reflectance source (R), fluorescence source
(F) and the first four detection fibers (A through D) are labeled. The
remaining detection fibers were not used in this study.
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At baseline, StO2 values clustered between ~45% and 65% in
the lesions of most patients. However, patient 9 had a pre-PDT
StO2 value of 16% and patients 5 and 10 had very low values of
<10%. Treatment-induced changes in lesion oxygenation were
detected in all patients, suggesting that PDT can alter the physio-
logic properties of even very superficial disease. At PDT conclu-
sion, lesion StO2 was >35% in all but patients 5 and 10. In
general, the magnitude of PDT effect on lesion StO2 was similar
among patients, although the direction of the change did vary.
Again, patient 10 was an exception; in this patient, a large
increase in StO2 was detected during the break in light delivery
for fractionation. Yet, irrespective of this increase at fraction-
ation, at the conclusion of PDT, lesion StO2 returned to a value
that was similar to its low baseline level. In this regard, it is
interesting to observe that the two patients (5 and 10) with the
poorest oxygenated disease at baseline and at the conclusion of
PDT were those who failed to achieve a complete response at
3 months.
In contrast to its effect on StO2, PDT tended to produce larger
and more variable changes in blood volume. In considering these
data, it is important to note that DRS measurements were made
very quickly (within seconds of the light being turned off) during
the dark interval of fractionation. In contrast, at the conclusion
of therapy, the illumination setup and shielding was removed
prior to beginning DRS measurements. This led to a potential
lapse of several minutes between therapy conclusion and physio-
logic measurements. These differences in the delay between ter-
mination of illumination and DRS measurements could lead to
inconsistencies in physiologic properties measured at a given flu-
ence, as a function of whether this fluence fell during the dark
interval of fractionation or at the conclusion of PDT. Measures
of [tHb] are likely particularly sensitive to this caveat, as PDT
can lead to rapid changes in blood flow (27).
Depth dependencies in lesion oxygenation are measureable
The DRS probe includes multiple detectors at different distances
from the source light fiber. This design provides for the depth-
averaged assessment of tissue physiology when data are averaged
across all of the detector fibers, as was done for the values
reported above. Alternatively, depth-dependent tissue oxygena-
tion can be obtained if the data are segregated as a function of
the separation between source and detector fibers in the optical
probe. The depth of the tissue interrogated by the broad-spectrum
source is approximately one-third to one-half of the distance
between the source and detector fiber. Thus, progressively deeper
tissue is probed by each detector that is positioned further from
the source fiber in the optical probe.
It is of interest to measure depth dependencies in tissue oxy-
genation because tumors are heterogeneously vascularized and/or
oxygenated, including along differentials that exist as a function
of their depth (28). Thus, we next considered if DRS could
detect any depth-dependent differences in lesion oxygenation.
DRS data were separated into that collected by detectors at posi-
tions of 0.14, 0.20, 0.28 and 0.34 cm from the source fiber,
Table 1. Patient characteristics.
Patient no. Histology Site Fluence (J cm2) PpIX fluorescence (a.u.) Response at 3 months*
1 High/severe dysplasia Tongue 50 93 CR
2 Carcinoma in situ Tongue 50 11 CR
3 High/severe dysplasia Junction of tongue/floor of mouth 50 17 CR
4 Moderate dysplasia Junction of tongue/alveolar ridge 100 18 CR
5 Moderate dysplasia Tongue 150 36 LR
6 Microinvasive carcinoma Tongue 150 51 CR
7 Moderate dysplasia Tongue 150 22 CR
8 Carcinoma in situ Buccal mucosa 200 52 CR
9 Moderate dysplasia Buccal mucosa 200 133 CR
10 High/severe dysplasia Junction of tongue/floor of mouth 200 85 LR
*Response at 3 months is characterized as complete response (CR) or local recurrence (LR).
Figure 2. (a) Typical diffuse reflectance spectra measured by the CFRS
system at different source-detector separations. (b) Fitting of the
1.37 mm spectrum. The spectrum considering negligible scattering, and
those considering only the absorption contributions of oxy- and deoxyhe-
moglobin are shown, along with the measured data and the fitting result.
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subsequently called positions A, B, C and D on the probe (see
Fig. 1 for schematic). Based on a depth probed that is ~50% of
the source-detector separation, the depth of tissue probed ranged
from the most superficial 0.07 cm of the lesion (at position A) to
within 0.17 cm of the lesion surface (at position D). These mea-
surement depths are well matched to the lesions of this study,
which by definition were 0.15 cm or less in depth excluding lim-
ited microfocal invasion of the basement membrane. Figure 4a
summarizes depth-dependent differences in lesion StO2 as a
function of source-detector separation. Paired differences in
median StO2 values were consistently positive when comparing
more superficial to deeper detectors. At the most superficial
pairing (A versus B), the median difference of 6.1% did not
achieve statistical significance. At the more distant pairings of A
with C and A with D, lesion oxygenation was significantly
higher at the lesion’s surface (respective median differences of
14.4% and 15.8%, P < 0.05 for both pairings). Similarly, at
intermediate depth the pairing of B with C (median difference of
10.0%, P = 0.014) was statistically significant for higher oxygen-
ation in the more superficial measurement; the pairing of B with
D was of a similar magnitude (median difference of 14.3%), but
did not achieve strict statistical significance (P = 0.105). At the
deepest regions probed, the median difference in lesion oxygena-
tion was only 2.3% between the fibers in the C and D positions.
These differences in StO2 are characteristic of the lesions
being measured. In contrast, normal tissue of the oral cavity
exhibits less variation with depth, as shown in Fig. 4b. The med-
ian paired difference ranged from 3.0 to 10.9% with only one
paired difference exceeding 10%. Only at the most superficial
depth comparison (A versus B) was the difference statistically
significant (P = 0.049, median difference of 8.5%), which is con-
sistent with the oxygenation of air-exposed mucosal and cutane-
ous surfaces through uptake of atmospheric oxygen (29,30).
Assessment of PpIX photobleaching
In addition to physiologic properties, tumor levels of PpIX dur-
ing the delivery of PDT are known to be predictive of treatment
effect (31,32). We have measured sensitizer fluorescence using
both the CFRS and NCTF systems. Typical fluorescence spectra
taken using these systems are shown in Fig. 5a,b. The compo-
nents of the fits to these data are also shown. The PpIX levels
measured using the contact probe varied by over 10-fold among
the lesions of different patients before PDT was begun (see
Table 1). As expected, PDT did produce substantial changes in
lesion PpIX levels. At treatment conclusion, most PpIX had
photobleached in the lesions (Fig. 6a). Moreover, photobleaching
occurred quickly, as low PpIX levels were detectable by the
break in light delivery for fractionation. It is important to empha-
size that for these measurements, only the most superficial layer
of the lesions was probed because PpIX was determined by its
fluorescence spectra following excitation at 403 nm. Given this
Figure 3. (a) Lesion StO2 and (b) [tHb] measured at baseline (0 J cm
2, first plotted point), during the dark interval of fractionation (second plotted
point) and at treatment conclusion (third plotted point). Lesions of the oral cavity were illuminated at 632 nm at 4–6 h after oral ingestion of ALA. Illu-
mination to the indicated light fluence was fractionated by a 90–180 s interruption of light delivery after 20% of the fluence. For clarity, panels separate
patients who were treated at different fluences.
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wavelength of excitation, most of the detected signal originated
from the tissue surface.
Using the treatment light as the excitation source with the
NCTF system, it is possible to probe for PpIX fluorescence in
deeper tissues on average than those sampled with the contact
probe. For measurements that used the treatment light, the photo-
bleaching time course, averaged over all patients at each fluence,
is shown in Fig. 6b. In general, these data show that the deeper
tissues bleach more slowly than the superficial layers, likely
because they receive a lower fluence rate of light. For example,
in patients treated at 50 J cm2, relative PpIX level was ~0.1 at
the tissue surface when illumination was paused at 10 J cm2
for the dark interval of fractionation (Fig. 6a). This can be com-
pared to that detected by more deeply probing measurements
(Fig. 6b), for which a relative PpIX level of ~0.5 was found at
the point of fractionation for 50 J cm2 (i.e. 10 J cm2). How-
ever, at the conclusion of the highest-light dose treatments, even
the deeper layers probed by treatment light are almost completely
photobleached.
DISCUSSION
In this study, we have demonstrated the feasibility of measuring
diffuse reflectance and fluorescence spectra as part of a clinical
protocol for superficial oral cavity lesions. The patient-to-patient
variations in both pre-existing optical properties and sensitizer
concentration and the changes induced by PDT were significant.
This has implications for patient-specific dosimetry. By prescrib-
ing a set measured fluence rate at the tissue surface, we use a
patient-specific dosimetry protocol that inherently accounts for
variations in patient geometry and optical properties and delivers
a prescribed fluence rate to the target tissue. Despite this, we still
see variations in response to PDT. Given the variation we see in
sensitizer fluorescence, this is not surprising. The next order of
refinement in patient-specific dosimetry could take one of two
courses.
The explicit dosimetry approach (15) would measure the flu-
ence rate of light, the sensitizer concentration and the tissue oxy-
genation. The dose would then be defined as the product of light
fluence and sensitizer concentration or by the cumulative singlet
oxygen concentration delivered to the tissue, as predicted by a
suitable model (33,34). Measurements such as those presented
here could provide the inputs for such a model. Explicit PDT
dosimetry is an area of ongoing investigation. The variability we
see among lesions in this study suggests that different patients
may require different fluence rates and different total fluences to
achieve similar therapeutic effects.
Alternatively, an implicit dosimetry strategy would use a sur-
rogate such as sensitizer photobleaching as an indicator of PDT
dose. The implicit dosimetry approach is in principle simpler
because it requires the measurement of only one parameter, the
fraction of the sensitizer that has been bleached. Our NCTF
Figure 4. (a) Depth-dependent differences in the pre-PDT oxygenation
of oral lesions and (b) normal tissues. Data plot the difference in tissue
StO2 measured by discrete pairings of the source fiber with detector fibers
in the DRS probe, thereby revealing differences in oxygenation between
the tissue depth measured by each source-detector pair. For simplicity,
detectors at a distance of 0.14, 0.20, 0.28 and 0.34 cm from the source
fiber are identified as positions A, B, C and D, respectively (see Fig. 1).
Differences in StO2 between each pair of positions are plotted as boxplots
with outliers identified as open circles. *Indicates P < 0.05 for a nonzero
depth-dependent difference.
Figure 5. (a) Typical fluorescence spectrum measured using the CFRS
system. The measured data are shown along with the fits and the contri-
butions of PpIX, autofluorescence and the sum of the remaining fitting
components. (b) Typical fluorescence spectrum excited by the treatment
light and collected by the NCTF system. The contributions from various
components are shown.
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measurements would provide the data needed to implement an
implicit dosimetry protocol. Again, although PpIX was bleached
in all cases, the variation in photobleaching rate indicates that
following an implicit PDT protocol could result in different flu-
ences and fluence rates for different patients.
Among these patients, lesion StO2 averaged 42  25% (SD)
at baseline. The majority of patients had values >45%, whereas
three patients had baseline values of <20%. Based on the oxyhe-
moglobin dissociation curve, a blood oxyhemoglobin saturation
of 50% is associated with an oxygen partial pressure of
~27 mmHg. This is well above the half value of 7.6 mmHg for
PDT-created cytotoxicity (35). It is only in patients 5, 9 and 10
at baseline and patients 5 and 10 after PDT that lesion StO2 val-
ues corresponded to oxygen partial pressures of less than
~15 mmHg, where limitations in PDT efficacy may come in to
play. Interestingly, both patients 5 and 10 had a local recurrence
at 3 months after PDT, which makes it of great interest to further
study the association between lesion oxygenation and PDT out-
comes.
The average baseline StO2 value of 42  25% was indistin-
guishable from an average value of 34  21% detected in the
normal oral tissues (data not shown). Others have also reported
the StO2 of normal mucosa and dysplastic lesions of the oral
cavity to be similar, whereas oxygenation of the mucosa of oral
squamous cell carcinoma is significantly lower (36,37). In these
studies, the average StO2 of oral tissue/cancer was between ~80
and 95%, compared to the averages of ~35–40% detectable in
our study. This difference may be attributable to the design of
the probes used for optical spectroscopy in each study. Our
probe interrogated tissue up to ~1.7 mm in depth (assuming a
measurement volume that extends to roughly one-half of the
maximum source-detector separation) and thus provides an aver-
age of the optical properties of tissues that include surface epi-
thelial tissue through underlying stroma (38). In the study by
Amelink et al. (37), the probe interrogated only within
~350 lM of the surface, (i.e. the epithelial layer), which was
more superficial than that measured by even our most closely
positioned source-detector pair (it measured to a depth
~0.7 mm). It is important to note here that we did detect depth-
dependent differences in lesion oxygenation showing that the
more superficial layers of the lesion are better oxygenated,
albeit the values did not reach the high StO2 percentages
reported by Amelink et al.
Others have also reported that depth-dependent variation
exists in the reflectance spectra of oral lesions (39). The authors
of this study concluded that the spectra in dysplastic or cancer-
ous tissue were more greatly affected by disease-induced differ-
ences in the light scattering properties of the epithelium than in
deeper underlying tissue (39). They hypothesized that this was a
result of changes in the nuclear composition of cells in the epi-
thelium as a function of disease progression (39,40). Moreover,
the presence of overlying keratin on the lesion or keratin pearls
deep within the epithelium, as is characteristic of oral (erythro)
leukoplakia (40), could contribute to architectural changes that
locally alter tissue physiology as detected by spectroscopy (36).
Overlying keratin could also explain the absence of an oxygen
differential between the two most superficial measurements (A–
B) in the lesions of our study (contrasted to the presence of a
differential in normal tissue). This follows the facts that keratin
overlying a lesion could impede the transmucosal diffusion of
oxygen and/or increase the distance between the mucosal layer
and probe contact with the tissue surface.
PDT led to both increases and decreases in lesion StO2 and
[tHb] in this study. These physiologic effects were detectable
both during the dark interval of fractionation and at treatment
conclusion. Using continuous measurements of tissue pO2 during
ALA-PDT of the rat colon, others have found that fractionation
leads to recoveries of tissue oxygenation after its decrease at the
initiation of light delivery (41). Also using continuous measure-
ments, Pogue et al. (10) documented progressive increases in the
pO2 of murine tumors during illumination for ALA-PDT that
remained elevated immediately after light delivery. They attrib-
uted these increases to contributions from a reduction in meta-
bolic oxygen consumption secondary to PDT-induced cell death
and/or PDT-created vascular effects. Yet, others have docu-
mented vasoconstriction to take place with PDT using topically
applied ALA (42,43), and both measurements and modeling sug-
gest that ALA-PDT can reduce local blood flow (44,45). Ulti-
mately, vascular effects during illumination for ALA-PDT are
highly dynamic (27), and the resulting oscillations in blood flow
Figure 6. (a) Photobleaching of PpIX measured by the CFRS system
(detector position A) at baseline (0 J cm2, first plotted point), during
the dark interval of fractionation (second plotted point) and at treatment
conclusion (third plotted point). Data are normalized to a value of 1
based on measurements made immediately before PDT (baseline); plots
indicate individual patients. (b) Photobleaching of PpIX fluorescence col-
lected by the NCTF system over the course of treatment. Measurements
made through excitation by the treatment light (probing more deeply than
the contact probe used to collect the data of panel (a). Data are normal-
ized to a value of 1 at the start of treatment, and plotted as the average
for each cohort. Error bars represent the standard deviation within each
cohort.
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make it quite possible that patient-to-patient differences will exist
in physiologic parameters for measurements made at a single
timepoint. Indeed, a clinical study of ALA-PDT in patients with
skin carcinoma (basal cell or squamous) documented variable
PDT effect on hemoglobin concentration (46). This result is not
unlike that which we have detected in this study. Overall, the
data from this trial are consistent with the possibility that lesion
physiologic status after PDT is determined by various factors,
such as PDT-induced ischemia or changes in oxygen consump-
tion, and the balance of the contributions by these factors will
likely vary among patients. Together with the above-described
studies, these data reaffirm the need to measure physiologic
parameters on an individual basis in patients.
Because of the potential for tumor concentrations of PpIX to
contribute to physiologic responses to PDT, we also evaluated
pre-existing and PDT effect on PpIX levels. Photobleaching pro-
duced very clear trends in PpIX levels during PDT that were
independent of physiologic properties or initial PpIX level. Most
photobleaching within the surface of the lesion (measured by a
source-detector separation of 0.14 cm using 405 nm illumina-
tion) occurred by the break for fractionation. These findings align
well with multiple other investigations that establish PpIX to be
rapidly photobleached by PDT (17,18,47). Nevertheless, it is
interesting that most photobleaching occurred by the time of
fractionation irrespective of the fluence delivered. Although this
suggests that the continued delivery of light may provide little
additional therapeutic benefit, it is crucial to remember that these
measurements reflect only the superficial photobleaching. Indeed,
in deeper tissue layers that were measured during the course of
illumination, photobleaching was detected throughout light deliv-
ery, with complete photobleaching reached near the conclusion
of the high fluence treatments. Thus, there is reason to expect
that in deeper layers the potential for a cytotoxic effect is
maintained throughout the treatment course.
In conclusion, this study demonstrates the feasibility of mak-
ing both contact and noncontact spectroscopic measurements dur-
ing PDT in the clinic, and also point out some key advantages
and disadvantages of each. Noncontact measurements have the
advantage that they can be made continuously during treatment,
and potentially used for dosimetry. Because they use treatment
light to excite fluorescence, the region sampled by the fluores-
cence measurements is closer to the volume being treated than in
the case of fluorescence excited by shorter wavelengths. On the
other hand, the CFRS system provides a wealth of data extracted
from diffuse reflectance measurement that is not available in the
noncontact measurements. Ultimately, both measurements could
be useful in clinical implementation of personalized PDT dosim-
etry. The CFRS system, or one with similar capabilities, could
be used to characterize the lesion before treatment and assess the
concentration of sensitizer and physiologic abnormalities that
might influence the selection of prescribed light dose. Ideally,
this measurement would be performed in an imaging mode,
rather than point-by-point. The technology to accomplish this has
been demonstrated in preclinical models (48,49). Then, the
NCTF system could be used to monitor photobleaching during
treatment to confirm that the prescribed dose is achieving the
intended biological effect. The present manuscript establishes the
clinical feasibility and utility of rationally designed spectroscopy
probes that can be employed toward personalized dosimetry in
PDT of the oral cavity, as well as at other potential treatment
sites.
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